Klorokin i hidroksiklorokin u terapiji karcinoma

Professional paper - Review paper

• Author: Branka Zorc
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of medicinal chemistry)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract (english)

Chloroquine and hydroxychloroquine are quinoline drugs used
for treatment and prevention of malaria. They are also diseasemodifying
antirheumatic drugs used for the treatment of various autoimmune
diseases: rheumatoid arthritis, systemic lupus erythematosus, porphyria cutanea
tarda, primary Sjogren syndrome, Lyme arthritis and antiphospholipid syndrome.
Over the past two decades, numerous studies have identified antitumor activities
of antimalarial drugs. The vast majority of studies focused on the sesquiterpene
lactones (artemisinines) and 4-aminoquinolines. Their anticancer effects were
evaluated as a part of ReDO project (Repurposing Drugs in Oncology). There are
also a large number of reports on natural products with antimalarial and concomitant
anticancer activity, produced by more than hundred species. Numerous
preclinical and clinical studies have been conducting to elucidate the efficacy and
safety profile of chloroquine or hydroxychloroquine in the therapy of different
cancer types, alone or in combination with conventional antitumor drugs, radiotherapy
or other therapeutic protocols. Many studies confirmed that they enhanced
effects of anticancer drugs in a synergistic manner via inducing apoptosis and/
or switching off autophagic and angiogenic machineries. However, they are considered
more as potential chemotherapy and radiotherapy sensitizers rather than
antineoplastic drugs. Maybe they will become soon old drugs with new uses.

• Keywords (croatian): klorokin; hidroksiklorokin; antitumorski lijekovi; antitumorsko djelovanje; tumor; karcinom
• Language: croatian
• Publication type: Professional paper - Review paper
• Publication status: Published
• Peer review: Peer review - domestic
• Publication version: Published version
• Journal title: Farmaceutski glasnik
• Numbering: vol. 77, no. 11-12, pp. 553-580
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:791321
• Publication: 2021
• Type of resource: Text
• Access conditions: Open access
• Created on: 2022-09-08 14:56:15